Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.

BJOG : an international journal of obstetrics and gynaecology - 1 Oct 2018

Rust K, Spiliopoulou P, Tang C Y, Bell C, Stirling D, Phang Thf, Davidson R, Mackean M, Nussey F, Glasspool R M, Reed N S, Sadozye A, Porteous M, McGoldrick T, Ferguson M, Miedzybrodzka Z, McNeish I A, Gourley C

Abstract excerpt

OBJECTIVE: To determine the rates of germline BRCA1 and BRCA2 mutations in Scottish patients with ovarian cancer, before and after a change in testing policy. DESIGN: Retrospective cohort study. SETTING: Four cancer/genetics centres in Scotland. POPULATION: Patients with ovarian cancer undergoing germline BRCA1 and BRCA2 (gBRCA1/2) sequencing before 2013 (under the 'old criteria', with selection based solely on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma

Share to Genetic Testing

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Prevalence

Share to Scotland

Source

Identifiers

PMID: 29460478
DOI: 10.1111/1471-0528.15171

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.PMID 29460478Read ↗

The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.Semantic proximity Read ↗

Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.Semantic proximity Read ↗

Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.Semantic proximity Read ↗

Mainstreamed genetic testing for women with ovarian cancer: first-year experience.Semantic proximity Read ↗

UK BRCA mutation testing in patients with ovarian cancer.Semantic proximity Read ↗

Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.Semantic proximity Read ↗

Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST StudySemantic proximity Read ↗

Pathology update to the Manchester Scoring System based on testing in over 4000 families.Semantic proximity Read ↗

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.Semantic proximity Read ↗

British Gynaecological Cancer Society/British Association of Gynaecological Pathology consensus for germline and tumor testing for BRCA1/2 variants in ovarian cancer in the United Kingdom.Semantic proximity Read ↗

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patientsSemantic proximity Read ↗

Insights for precision healthcare from the 100,000 Genomes Cancer ProgrammeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.